3.9
Impact Factor
6.8
CiteScore
22 days
Time to First Decision

Biomedicines, Volume 3, Issue 4

2015 December - 3 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (3)

Select all

Article

14 Citations

5,722 Views

12 Pages

Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms’ Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination

Yumiko Higuchi,
Terutsugu Koya,
Miki Yuzawa,
Naoko Yamaoka,
Yumiko Mizuno,
Kiyoshi Yoshizawa,
Koichi Hirabayashi,
Takashi Kobayashi,
Kenji Sano and
Shigetaka Shimodaira

Biomedicines2015, 3(4), 304-315;https://doi.org/10.3390/biomedicines3040304

4 December 2015

Background: Despite recent advances in cancer immunotherapy and the development of various assays for T cell assessment, a lack of universal standards within immune monitoring remains. The objective of this study was to evaluate the enzyme-linked imm...

Full Article

Feature Paper
Review

22 Citations

11,047 Views

22 Pages

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation

Simone P. Sittig,
I. Jolanda M. De Vries and
Gerty Schreibelt

Biomedicines2015, 3(4), 282-303;https://doi.org/10.3390/biomedicines3040282

2 December 2015

Dendritic cell (DC)-based cancer vaccines hold the great promise of tipping the balance from tolerance of the tumor to rejection. In the last two decades, we have gained tremendous knowledge about DC-based cancer vaccines. The maturation of DCs has p...

Full Article

Review

12 Citations

6,084 Views

12 Pages

Circulating MicroRNAs as Biomarkers and Mediators of Cell–Cell Communication in Cancer

Molly A. Taylor

Biomedicines2015, 3(4), 270-281;https://doi.org/10.3390/biomedicines3040270

9 November 2015

The realization of personalized medicine for cancer will rely not only on the development of new therapies, but on biomarkers that direct these therapies to the right patient. MicroRNA expression profiles in the primary tumor have been shown to diffe...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Biomedicines - ISSN 2227-9059

Imprint

Download Flyer